Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Jun 13, 2023 11:25am
100 Views
Post# 35493722

RE:Very encouraging, but approval will take time

RE:Very encouraging, but approval will take timeGot my SPECT scan yesterday using Ga68-Dotatate. It is so easy and they can see everything with high resolution, tiny tumors, all based on somatostatin receptor. Doctor Meric did a comparison what is done with ADCs, but TH1902 is not an ADC, it's a PDC, like Ga68-Dotatate.

I know they don't have the financial means to develop that at this point, but it would be so helpful going forward. It would act as a prcision imaging tool and as a patient selection tool. They need to think PDC, not ADC. Yes, both are targeted, but you compare an aircraft carrier with a military drone boat.

In my case, after they saw progression of my cancer back in February on SPECT with Ga68, they sent me to pass a standard CT scan, just to see if they were able to see the new small tumors with it, and standard CT scan was unable to show them clearly, so they will follow me with SPCET Ga68 scans moving forward.  My point is that they need to think PDC, not ADC.
<< Previous
Bullboard Posts
Next >>